Last reviewed · How we verify
PREDNISONE
PREDNISONE is a Corticosteroid [EPC] drug. It is currently FDA-approved (first approved 1955).
PREDNISONE is a small molecule used in various clinical trials for conditions such as Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, and Recurrent Prostate Cancer. It is not directly mentioned as an intervention in the provided ClinicalTrials.gov information, suggesting it may be used as a standard chemotherapy or in combination with other treatments like Epcoritamab, Lenalidomide, and Rituximab.
At a glance
| Generic name | PREDNISONE |
|---|---|
| Drug class | Corticosteroid [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1955 |
Approved indications
Common side effects
- Congestive heart failure in susceptible patients
- Peptic ulcer with possible perforation and hemorrhage
- Pancreatitis
- Ulcerative esophagitis
- Pathologic fracture of long bones
- Aseptic necrosis of femoral and humeral heads
- Vertebral compression fractures
- Osteoporosis
- Glaucoma
- Increased intraocular pressure
- Exophthalmos
- Convulsions
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement (NA)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PREDNISONE CI brief — competitive landscape report
- PREDNISONE updates RSS · CI watch RSS
Frequently asked questions about PREDNISONE
What is PREDNISONE?
What drug class is PREDNISONE in?
When was PREDNISONE approved?
What development phase is PREDNISONE in?
What are the side effects of PREDNISONE?
Related
- Drug class: All Corticosteroid [EPC] drugs
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing